Cannabinoid receptors CB1 in schizophrenia role of brain mitochondrial activity...
Cannabinoid receptors CB1 in schizophrenia role of brain mitochondrial activity and astroglial signalling
"Schizophrenia is a severe psychiatric disorder characterized by a series of ""positive"" and ""negative"" symptoms, which eventually lead to strong sufferance, social isolation and occupational impairment. Via activation of type-...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
RTI2018-095311-B-I00
EN BUSCA DE NUEVOS INTERACTORES DEL RECEPTOR CB1 CANNABINOID...
399K€
Cerrado
PID2019-107548RB-I00
RECEPTORES DE CANNABINOIDES LOCALIZADOS EN MICROGLIA EN UN M...
214K€
Cerrado
PID2021-125118OB-I00
EL RECEPTOR CB1 CANNABINOIDE COMO POSIBLE NEXO MOLECULAR EN...
327K€
Cerrado
MiCaBra
Mitochondrial Cannabinoid Receptors in the Brain
3M€
Cerrado
SAF2009-07309
MECANISMOS MOLECULARES IMPLICADOS EN LA MODULACION DE LA MEM...
109K€
Cerrado
SAF2015-64945-R
IDENTIFICACION Y CARACTERIZACION DE SUBPOBLACIONES DEL RECEP...
399K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"Schizophrenia is a severe psychiatric disorder characterized by a series of ""positive"" and ""negative"" symptoms, which eventually lead to strong sufferance, social isolation and occupational impairment. Via activation of type-1 cannabinoid receptors (CB1), cannabinoids are known to induce schizophrenic-like symptoms, which are major caveats in the possible therapeutic use of these compounds. On the other hand, mitochondria-dependent regulation of brain bioenergetics is emerging as a promising novel research path in the field of psychopathology of schizophrenia. Previous results suggest the implication of mitochondrial (mtCB1) and astrocytic-CB1 receptors in psychotic-like conditions. However the precise molecular and cellular links between ECS activity and schizophrenia are not known. The aim of this study is to test whether mithocondrial and/or astrocytic CB1 receptors represent a functional link between endocannabinoid signalling in the brain and psychotic-like behaviours. (1) Firstly, the project will be dedicated to the generation of specific genetic tools to clearly discriminate mtCB1 from other CB1 receptor locations in the cell. (2) Then, these specific tools and specific transgenic mice will be used to investigate the role of mtCB1 and astrocytic-CB1 receptor in ""psychosis-like"" effects of cannabinoid drugs, and (3) to study the role of these receptors in a schizophrenia-like mouse model. This project will improve our understanding of the pathophysiology of psychotic-like disorders and might pave the way to novel therapeutic opportunities to improve the life of patients."